O’Melveny Represents TenNor Therapeutics in Approximate US$80 Million Chapter 18A Hong Kong IPO
May 22, 2026
FOR IMMEDIATE RELEASE
HONG KONG—May 22, 2026—O’Melveny represented TenNor Therapeutics (Suzhou) Limited (“TenNor Therapeutics”, 6872.HK) in its initial public offering and listing on the Main Board of the Hong Kong Stock Exchange. The total offering size was approximately HK$627 million (approximately US$80 million). O’Melveny acted as Hong Kong and U.S. counsel to TenNor Therapeutics and drafted the prospectus. CITIC Securities (Hong Kong) Limited and ABCI Capital Limited acted as the joint sponsors.
TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address medical needs in disease areas associated with bacterial infections and bacterial metabolism. The company has built a pipeline of seven drug candidates, as of May 4, 2026, including two core products: rifasutenizol (TNP-2198), the world’s first and only new molecular entity (NME) drug candidate developed for the treatment of H. pylori infection, and rifaquizinone (TNP-2092 injection), the world’s first NME drug candidate with the potential to be effective against biofilm infections at clinically achievable doses.
This is the firm’s 23rd Chapter 18A listing overall and third this year. O’Melveny has advised on over a quarter of all biotech company IPOs since the Chapter 18A of Hong Kong’s Main Board Listing Rules were adopted in 2018. Notably, this is the firm’s sixth completed medical listing of the year, following the IPOs of Ribo Life Science, Distinct Healthcare Holdings, Diagens Biotechnology, Cofoe Medical Technology, and Metis TechBio.
The O’Melveny team was led by partners Ke Geng and Ke Zhu. The core team members included counsel Stella Hu, associates Jingwei Huang, Fan Wu, Minhui Chen and Alfred Li, and legal manager Cherika Chan. Legal consultant Zheng Li also provided valuable support.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #